In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...

Episode 10 (February 23, 2024): Researchers from Francis Collins’ lab developed an efficient CRISPR prime editing protocol to generate isogenic-induced pluripotent stem cell (iPSC) lines carrying ...

CRISPR-Cas9 editing leads to widespread loss of the targeted chromosome in human T cells, but scientists recently discovered a way to prevent such loss. To investigate how Cas9 gene editing affected T ...

Conference call today at 8:30 a.m. ETCAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

The CRISPR/Cas9 system, typically abbreviated to just CRISPR, has been used to edit genomes with increasing frequency over the past few years. The name refers to specialized stretches of DNA that we ...

Despite the copious demands of his administrative positions as the White House chief science advisor (and until last year, the director of the NIH), Francis Collins, MD, PhD, has continued to run a ...

Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as ...